FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

Estimated average burden hours per response: 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(c). Se	e Instruction 10).																	
1. Name and Address of Reporting Person* <u>Anand Bhaskar</u>						2. Issuer Name and Ticker or Trading Symbol Summit Therapeutics Inc. [SMMT]									5. Relationship of Reporting (Check all applicable) Director Officer (give title			10% Ov	/ner
(Last) (First) (Middle) C/O SUMMIT THERAPEUTICS INC. 601 BRICKELL KEY DRIVE, SUITE 1000						3. Date of Earliest Transaction (Month/Day/Year) 10/21/2025									X Officer (give title below) Other (specify below) Chief Accounting Officer				
(Street) MIAMI FL 33131 (City) (State) (Zip)				4. If <i>I</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc Line)	Form	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired	, Dis	posed of	, or E	Bene	eficiall	y Own	ed			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						Exec if any	eemed ition Date, h/Day/Year)		3. Transaction Code (Instr. 8) 4. Securitie Disposed (5)			s Acqu of (D) (li	ired (nstr. 3	A) or 3, 4 and	5. Amount of Securities Beneficially Owned Followin Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Ownership
									Code	v	Amount	(A) (D)	or	Price	Transa	ction(s) 3 and 4)			Instr. 4)
Common Stock 10/21/20)25		A		26,680(1)	A		\$18.74	159	59,751(2)				
		Tal	ole II -								osed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Dat (Month/Day/Ye		ite	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se	Price of erivative ecurity estr. 5)		Owner Form: Direct or Indi (I) (Ins		11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Nun of						

Explanation of Responses:

- 1. Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of \$18.74 per share. The transaction is anticipated to close on or about October 23, 2025.
- 2. Holdings include shares previously acquired through exempt transactions pursuant to the Issuer's employee stock purchase plan.

Remarks:

/s/ Bhaskar Anand

10/23/2025 Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.